Want to see IRON full AI Analyst Report?
Top Page
Disc Medicine
(NASDAQ:IRON)
Select Model
Select Model
Rating:54Neutral
Price Target:
$65.00
▼(-21.13% Downside)
Action:Reiterated
Date:09/10/26
The score is held back primarily by the pre-revenue profile with rapidly expanding losses and heavy cash burn, despite a strong low-debt balance sheet. Technicals also lean soft near-term (below key short-term moving averages with sub-50 RSI). Offsetting these risks, corporate updates were constructive, led by encouraging Phase 2 data and improved financing flexibility.
Positive Factors
Promising Phase 2 efficacy
The Phase 2 data provide clinical support for DISC-3405 in polycythemia vera, including durable hematocrit control and fewer phlebotomies over 26 weeks. These results may strengthen the program’s path toward pivotal development and improve its potential to address a significant treatment burden.
Negative Factors
Pre-revenue business model
Disc Medicine has no current product revenue to offset research and operating expenses, leaving its financial model dependent on capital raising or potential business-development proceeds. Until a therapy is approved and launched, funding needs remain structurally tied to clinical progress and investor support.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising Phase 2 efficacy
The Phase 2 data provide clinical support for DISC-3405 in polycythemia vera, including durable hematocrit control and fewer phlebotomies over 26 weeks. These results may strengthen the program’s path toward pivotal development and improve its potential to address a significant treatment burden.
Read all positive factors
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.48B
Dividend YieldN/A
Average Volume (3M)541.11K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS Growth-47.00%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.60
Shares Outstanding38,392,845
10 Day Avg. Volume567,470
30 Day Avg. Volume541,105
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.99
Forecast
1Y Price Target
$102.22Price Target Upside24.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.42
Revenue Forecast (FY)N/A
Disc Medicine Business Overview & Revenue Model
Company Description
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from se...
How the Company Makes Money
Disc Medicine is a clinical-stage biotech and, as such, does not typically generate recurring revenue from marketed products; its cash inflows generally come from financing and, where applicable, business development arrangements. The company’s pr...
Disc Medicine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -241.67M | -207.94M | -108.27M | -76.23M | -46.74M | -33.78M |
| Net Income | -245.89M | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | ||||||
| Total Assets | 735.07M | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 717.75M | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 60.86M | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 90.91M | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 644.16M | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | ||||||
| Free Cash Flow | -197.58M | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -197.54M | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -93.42M | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 262.30M | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Negative
82.41
Price Trends
74.67
Negative
73.15
Negative
71.67
Negative
Market Momentum
-3.30
Positive
27.88
Positive
7.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Negative. The current price of 82.41 is above the 20-day moving average (MA) of 68.17, above the 50-day MA of 74.67, and above the 200-day MA of 71.67, indicating a bearish trend. The MACD of -3.30 indicates Positive momentum. The RSI at 27.88 is Positive, neither overbought nor oversold. The STOCH value of 7.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRON.
Disc Medicine Risk Analysis
Disc Medicine disclosed 82 risk factors in its most recent earnings report. Disc Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Disc Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $880.76M | 2.70 | 96.49% | ― | 3.31% | 221.64% | |
59 Neutral | $1.90B | -4.46 | -35.67% | ― | 140.58% | -161.11% | |
58 Neutral | $1.35B | 9.90 | -109.40% | ― | ― | ― | |
56 Neutral | $770.97M | -12.14 | -30.31% | ― | 24.39% | 21.06% | |
54 Neutral | $2.48B | -9.60 | -37.17% | ― | ― | -47.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IRON
Disc Medicine
63.33
-4.56
-6.72%
GERN
Geron
1.21
-0.08
-6.20%
OMER
Omeros
18.90
14.46
325.68%
RIGL
Rigel
47.79
18.29
62.00%
AGIO
Agios Pharma
31.25
-9.62
-23.54%
COAG
Hemab Therapeutics Holdings, Inc.
30.59
-3.41
-10.03%
Disc Medicine Corporate Events
Business Operations and Strategy
Disc Medicine reports promising DISC-3405 Phase 2 data
Positive
Sep 10, 2026
On September 9, 2026, Disc Medicine presented initial data from its Phase 2 RESTORE-PV trial of DISC-3405 in patients with polycythemia vera at the Society of Hematologic Oncology annual meeting. In Cohort A, the investigational antibody increased...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.